Published in Ann Diagn Pathol on December 01, 2000
Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun (2005) 1.59
Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun (2002) 1.54
Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun (2007) 1.40
Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression. Infect Immun (2010) 1.00
Immunoglobulin M antibody responses to Mycobacterium ulcerans allow discrimination between cases of active Buruli ulcer disease and matched family controls in areas where the disease is endemic. Clin Diagn Lab Immunol (2004) 0.87
Under treated necrotizing fasciitis masquerading as ulcerated edematous Mycobacterium ulcerans infection (Buruli ulcer). Am J Trop Med Hyg (2010) 0.78
Predominance of a single genotype of Mycobacterium tuberculosis in countries of east Asia. J Clin Microbiol (1995) 15.19
Analysis of the population structure of Mycobacterium tuberculosis in Ethiopia, Tunisia, and The Netherlands: usefulness of DNA typing for global tuberculosis epidemiology. J Infect Dis (1995) 6.95
Characterization of rifampin-resistance in pathogenic mycobacteria. Antimicrob Agents Chemother (1994) 5.64
Spectrum of immunodeficiency in HIV-1-infected patients with pulmonary tuberculosis in Zaire. Lancet (1993) 5.52
A novel pathogenic taxon of the Mycobacterium tuberculosis complex, Canetti: characterization of an exceptional isolate from Africa. Int J Syst Bacteriol (1997) 5.28
Diagnosis of Mycobacterium microti infections among humans by using novel genetic markers. J Clin Microbiol (1998) 4.83
Insects in the transmission of Mycobacterium ulcerans infection. Lancet (1999) 4.46
Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tuber Lung Dis (1995) 3.83
Proposed minimal standards for the genus Mycobacterium and for description of new slowly growing Mycobacterium species. Int J Syst Bacteriol (1992) 3.65
Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin. Antimicrob Agents Chemother (1997) 3.55
Identification of Mycobacterium species by using amplified ribosomal DNA restriction analysis. J Clin Microbiol (1993) 3.38
Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med (1995) 3.09
Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. Int J Tuberc Lung Dis (1999) 3.08
Variability in 3' end of 16S rRNA sequence of Mycobacterium ulcerans is related to geographic origin of isolates. J Clin Microbiol (1996) 3.07
DNA probes demonstrate a single highly conserved strain of Mycobacterium avium infecting AIDS patients. Lancet (1989) 2.91
Mycobacterium ulcerans in wild animals. Rev Sci Tech (2001) 2.84
Fatal strongyloidiasis in immunosuppressed patients. Am J Med (1974) 2.76
Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Int J Tuberc Lung Dis (2000) 2.71
IS901, a new member of a widespread class of atypical insertion sequences, is associated with pathogenicity in Mycobacterium avium. Mol Microbiol (1991) 2.64
Direct detection and identification of Mycobacterium ulcerans in clinical specimens by PCR and oligonucleotide-specific capture plate hybridization. J Clin Microbiol (1997) 2.50
A simple PCR method for rapid genotype analysis of Mycobacterium ulcerans. J Clin Microbiol (2000) 2.43
Geographically distinct isolates of Mycobacterium leprae exhibit no genotypic diversity by restriction fragment-length polymorphism analysis. Mol Microbiol (1990) 2.25
Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis (2004) 2.20
Biologically distinct subtypes of Mycobacterium avium differ in possession of insertion sequence IS901. J Clin Microbiol (1992) 2.18
Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis (2004) 2.08
Pulmonary tuberculosis in prisons of the ex-USSR state Georgia: results of a nation-wide prevalence survey among sentenced inmates. Int J Tuberc Lung Dis (2000) 2.01
Detection and identification of mycobacteria by DNA amplification and oligonucleotide-specific capture plate hybridization. J Clin Microbiol (1995) 1.94
Human Mycobacterium ulcerans infections developing at sites of trauma to skin. Am J Trop Med Hyg (1974) 1.89
Evaluation of mycobacteria growth indicator tube for direct and indirect drug susceptibility testing of Mycobacterium tuberculosis from respiratory specimens in a Siberian prison hospital. J Clin Microbiol (2001) 1.85
Rapid identification of Mycobacteria to the species level using INNO-LiPA Mycobacteria, a reverse hybridization assay. J Clin Microbiol (2001) 1.85
Effects of decontamination methods and culture conditions on viability of Mycobacterium ulcerans in the BACTEC system. J Clin Microbiol (1998) 1.85
Comparison of two PCRs for detection of Mycobacterium ulcerans. J Clin Microbiol (1999) 1.82
In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob Agents Chemother (1998) 1.80
Multidrug-resistant tuberculosis in prison inmates, Azerbaijan. Emerg Infect Dis (2001) 1.75
[Epidemiology of ulcers due to Mycobacterium ulcerans]. Ann Soc Belg Med Trop (1989) 1.74
Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1999) 1.69
Characterization of an unusual Mycobacterium: a possible missing link between Mycobacterium marinum and Mycobacterium ulcerans. J Clin Microbiol (2002) 1.67
Mycobacterium ulcerans infection (Buruli ulcer): first reported patients in Togo. Br J Dermatol (1996) 1.67
Evaluation of Mycobacteria Growth Indicator Tube (MGIT) for drug susceptibility testing of Mycobacterium tuberculosis. Int J Tuberc Lung Dis (1999) 1.63
[Buruli ulcer: risk of bone involvement! Apropos of 33 cases observed in Benin]. Med Trop (Mars) (2000) 1.63
Results of a national survey on drug resistance among pulmonary tuberculosis patients in Rwanda. Int J Tuberc Lung Dis (2007) 1.62
Simple procedure for drug susceptibility testing of Mycobacterium tuberculosis using a commercial colorimetic assay. Eur J Clin Microbiol Infect Dis (1999) 1.59
The use of IS2404 restriction fragment length polymorphisms suggests the diversity of Mycobacterium ulcerans from different geographical areas. Am J Trop Med Hyg (2001) 1.54
Evaluation of tuberculosis control by periodic or routine susceptibility testing in previously treated cases. Int J Tuberc Lung Dis (2001) 1.53
In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. J Antimicrob Chemother (2000) 1.50
Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer. Infect Immun (2001) 1.50
Evaluation of PCR-restriction profile analysis and IS2404 restriction fragment length polymorphism and amplified fragment length polymorphism fingerprinting for identification and typing of Mycobacterium ulcerans and M. marinum. J Clin Microbiol (2001) 1.49
Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. J Infect Dis (2000) 1.48
Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Trop Med Int Health (2004) 1.48
Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun (2004) 1.48
Characterization of the virulence of Mycobacterium avium complex (MAC) isolates in mice. Clin Exp Immunol (1994) 1.47
[Mycobacterium ulcerans cutaneous infections: Buruli ulcers]. Med Trop (Mars) (1995) 1.44
Multicenter study of MTT and resazurin assays for testing susceptibility to first-line anti-tuberculosis drugs. Int J Tuberc Lung Dis (2005) 1.43
Cytotoxic activity of Mycobacterium ulcerans. Infect Immun (1974) 1.42
Kanamycin susceptibility testing of Mycobacterium tuberculosis using Mycobacterium Growth Indicator Tube and a colorimetric method. Antimicrob Agents Chemother (2001) 1.40
Leprosy research and patient care over the past century. Int J Lepr Other Mycobact Dis (1998) 1.40
Studies on Mycobacterium chelonei. J Med Microbiol (1972) 1.40
Fatty and mycolic acids of Mycobacterium malmoense. J Clin Microbiol (1988) 1.40
Further studies on African strains of Mycobacterium tuberculosis: comparison with M. bovis and M. microti. Ann Soc Belges Med Trop Parasitol Mycol (1970) 1.38
Rhodococcus equi infection in 3 AIDS patients. Acta Clin Belg (1996) 1.38
Mycobacteriosis caused by Mycobacterium genavense in birds kept in a zoo: 11-year survey. J Clin Microbiol (1996) 1.38
Immunosuppressive properties of the soluble toxin from Mycobacterium ulcerans. J Infect Dis (1988) 1.33
Limitations and requirements for quality control of sputum smear microscopy for acid-fast bacilli. Int J Tuberc Lung Dis (1998) 1.32
First molecular epidemiological study of tuberculosis in Benin. Int J Tuberc Lung Dis (2009) 1.28
Anti-tuberculosis drug resistance among new and previously treated pulmonary tuberculosis patients in Cotonou, Benin. Int J Tuberc Lung Dis (2007) 1.27
Evaluation of amplified fragment length polymorphism analysis for inter- and intraspecific differentiation of Mycobacterium bovis, M. tuberculosis, and M. ulcerans. J Clin Microbiol (2000) 1.26
Drug resistance monitoring: combined rates may be the best indicator of programme performance. Int J Tuberc Lung Dis (2004) 1.24
Distribution of Mycobacterium ulcerans infections in Zaire, including the report of new foci. Ann Soc Belg Med Trop (1974) 1.23
Bleach sedimentation method for increased sensitivity of sputum smear microscopy: does it work? Int J Tuberc Lung Dis (2000) 1.20
Impact of short-course therapy on tuberculosis drug resistance in South-West Burkina Faso. Tuber Lung Dis (1996) 1.19
First reported case of Mycobacterium ulcerans infection in a patient from China. Trans R Soc Trop Med Hyg (2000) 1.19
Evaluation of a commercial line probe assay for identification of mycobacterium species from liquid and solid culture. Eur J Clin Microbiol Infect Dis (2002) 1.15
Growth of mycobacteria in relation to the pH of the medium. Ann Microbiol (Paris) (1983) 1.14
Mycolic acid patterns of four vaccine strains of Mycobacterium bovis BCG. J Gen Microbiol (1983) 1.14
Heat treatment of Mycobacterium ulcerans infections without surgical excision. Am J Trop Med Hyg (1974) 1.14
[Traditional treatment for Buruli ulcer in Benin]. Med Trop (Mars) (2004) 1.13
The local immune response in ulcerative lesions of Buruli disease. Clin Exp Immunol (2006) 1.13
Effect of oxygen on growth of Mycobacterium ulcerans in the BACTEC system. J Clin Microbiol (1998) 1.12
Mycotic granuloma caused by Phialophora repens. Am J Clin Pathol (1975) 1.10
Experimental leprosy in three species of monkeys. Science (1985) 1.09
Evaluation of a rapid culture method for tuberculosis diagnosis: a Latin American multi-center study. Int J Tuberc Lung Dis (2006) 1.09
Species-specific Mycobacterium genavense DNA in intestinal tissues of individuals not infected with human immunodeficiency virus. J Clin Microbiol (1995) 1.09
A cooperative taxonomic study of mycobacteria isolated from armadillos infected with Mycobacterium leprae. J Gen Microbiol (1986) 1.09
Epidemiological and genetic markers, virulence factors and intracellular growth of Mycobacterium avium in AIDS. Res Microbiol (1992) 1.09
Leprosy. JAMA (1982) 1.09
Prophylactic effect of mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer). Clin Diagn Lab Immunol (2002) 1.08